Literature DB >> 6731047

Polymorphism of complement C3 in chronic inflammatory bowel disease. Predominance of the C3F gene in Crohn's disease.

J Elmgreen, H Sørensen, A Berkowicz.   

Abstract

Polymorphism of the third component of complement (C3), occupying a key position in cascade reactions, was investigated in 125 consecutive outpatients, 53 with Crohn's disease and 72 with ulcerative colitis. A sample of 1378 randomly selected healthy volunteers of Danish origin served as controls. Occurrence of the F and FS phenotype of C3 (C3F and C3FS ) was increased in the group of Crohn's disease patients (chi 2 = 2.80, p less than 0.05, one-tailed test) and in a subgroup of Crohn patients with the gastrointestinal disease process confined to ileum (chi 2 = 6.91, p less than 0.01). C3 phenotype distribution was unaffected in ulcerative colitis. Only S and F alleles of C3 ( C3S and C3F) were recognized and C3F frequencies were 0.33 in Crohn patients with small bowel disease, 0.23 in all Crohn patients, 0.18 in ulcerative colitis patients and 0.17 in healthy volunteers. The results are compatible with a positive association of the C3F gene and Crohn's disease located in the small bowel.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6731047     DOI: 10.1111/j.0954-6820.1984.tb05021.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  11 in total

1.  Inflammatory bowel disease: definition, epidemiology, etiologic aspects, and immunogenetic studies.

Authors:  Bing Xia; JBA Crusius; SGM Meuwissen; AS Pe?a
Journal:  World J Gastroenterol       Date:  1998-10       Impact factor: 5.742

2.  Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics.

Authors:  E A Vasiliauskas; L Y Kam; L C Karp; J Gaiennie; H Yang; S R Targan
Journal:  Gut       Date:  2000-10       Impact factor: 23.059

3.  Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci.

Authors:  J D Rioux; M S Silverberg; M J Daly; A H Steinhart; R S McLeod; A M Griffiths; T Green; T S Brettin; V Stone; S B Bull; A Bitton; C N Williams; G R Greenberg; Z Cohen; E S Lander; T J Hudson; K A Siminovitch
Journal:  Am J Hum Genet       Date:  2000-04-21       Impact factor: 11.025

4.  C4B gene influences intestinal microbiota through complement activation in patients with paediatric-onset inflammatory bowel disease.

Authors:  E Nissilä; K Korpela; A I Lokki; R Paakkanen; S Jokiranta; W M de Vos; M-L Lokki; K-L Kolho; S Meri
Journal:  Clin Exp Immunol       Date:  2017-09-25       Impact factor: 4.330

5.  Genetics of inflammatory bowel disease.

Authors:  J Satsangi; D P Jewell; W M Rosenberg; J I Bell
Journal:  Gut       Date:  1994-05       Impact factor: 23.059

6.  Crohn's disease: the genetic contribution.

Authors:  J Sofaer
Journal:  Gut       Date:  1993-07       Impact factor: 23.059

7.  Polymorphisms in complement component 3 (C3F) and complement factor H (Y402H) increase the risk of postoperative neurocognitive dysfunction following carotid endarterectomy.

Authors:  Paul R Gigante; Ivan S Kotchetkov; Christopher P Kellner; Raqeeb Haque; Andrew F Ducruet; Brian Y Hwang; Robert A Solomon; Eric J Heyer; E Sander Connolly
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-09-14       Impact factor: 10.154

8.  Immunoglobulin G subclass distribution of anti-endothelial cell antibodies (AECA) in patients with ulcerative colitis or Crohn's disease.

Authors:  D Aldebert; E Masy; D Reumaux; G Lion; J F Colombel; P Duthilleul
Journal:  Dig Dis Sci       Date:  1997-11       Impact factor: 3.199

9.  Molecular characterization of the pig C3 gene and its association with complement activity.

Authors:  Klaus Wimmers; Supamit Mekchay; Karl Schellander; Siriluck Ponsuksili
Journal:  Immunogenetics       Date:  2003-01-09       Impact factor: 2.846

10.  Different allotypes of C3 degrade at different rates.

Authors:  P H Kay; S Natsuume-Sakai; J Hayakawa; R L Dawkins
Journal:  Immunogenetics       Date:  1985       Impact factor: 2.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.